Barry Greene

Dr. Barry E. Greene, MD, is an Independent Director at BCLS Acquisition Corp., a President, Chief Executive Officer & Director at SAGE Therapeutics, Inc., a Chief Medical Officer at Vicarious Surgical, Inc., a Lead Independent Director at Karyopharm Therapeutics, Inc. and an Independent Director at Acorda Therapeutics, Inc. He is on the Board of Directors at BCLS Acquisition Corp., SAGE Therapeutics, Inc., Karyopharm Therapeutics, Inc. and Acorda Therapeutics, Inc. Dr. Greene was previously employed as an Independent Director by Ambrx, Inc., a President by Alnylam Pharmaceuticals, Inc., a General Manager-Oncology Division by Takeda Oncology Co., a Vice President-Marketing & Customer Services by AstraZeneca Plc, a Partner by Andersen Consulting LLP (GB), a Partner by Accenture Ltd., a Vice President-Strategic Integration by AstraZeneca Pharmaceuticals LP, and a Chief Business Officer & Executive Vice President by Mediconsult.com, Inc. He also served on the board at Intercept Pharmaceuticals, Inc. and Regulus Therapeutics, Inc. He received his undergraduate degree from the University of Pittsburgh.